Topic summary
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry
This is a generated summary. It shows the 5 most-liked posts from a topic of 15, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
IRenaudin, post #2: Fine by me. I had wanted a stronger conclusion and there is not one available. Go to post
Building on post #5 rather than restating it.
Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is mechanistically plausible for benefit in metabolic liver disease. Whether that translates to improved clinical outcomes is being tested in phase 2 work.
Two people can read the same figure differently here and both be reasonable.
t.varga, post #3: Offering a way to settle Hepatic effects of glucagon receptor rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision. Go to post
Helpful, and short, which on this subject is harder than long.
Taking post #10 at face value and following it one step further.
Triple agonism at GLP-1, GIP and glucagon receptors is the defining feature and the glucagon limb is the one people find counter-intuitive. It raises energy expenditure and promotes hepatic fat oxidation, and the incretin limbs offset the glycaemic consequence.
26 likes 5d
Read the full topic (15 posts)
This topic was referenced in
- Second pass at: Retatrutide dose escalation in the published trialsCompounds › Retatrutide · 125 replies
Promoted into the documentation commons. The content of this topic is maintained at Retatrutide — reference, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Retatrutide's phase 2 heart-rate signal and how to think about it
On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a…
|
+19 | 23 | 20k | 7mo |
|
Second pass at: Triple agonism: additive, synergistic, or neither?
Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a small dataset on Triple agonism. It is…
|
+114 | 120 | 1.4k | 10mo |
|
Retatrutide phase 2 in type 2 diabetes: the Lancet paper
On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. Asking about retatrutide phase 2 in type on behalf of the question I keep seeing…
|
+12 | 16 | 50k | 12mo |
|
The retatrutide phase 2 obesity paper, read closely
Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that. Retatrutide phase 2 obesity paper, from the point of view of someone…
|
2 | 65k | 10mo | |
|
Why retatrutide discussion here is more cautious than elsewhere
Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. A question about retatrutide discussion that I think…
|
+7 | 12 | 7.7k | 2mo |
Related topics — sharing the tags retatrutide, randomised trial, effect size
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Retatrutide mass and identity: what a report should show
Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
|
+65 | 71 | 4.6k | 13mo |
|
When a network meta-analysis is defensible and when it is not
When a network meta-analysis is defensible and when it is not I have a specific reason for asking rather than idle curiosity, and the context is below. Network meta-analysis, from the point of view of someone…
|
2 | 27k | 4h | |
|
Journal club: LEADER as the historical anchor
Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of LEADER is wrong? I ask because I have…
|
+103 | 110 | 8.1k | 2h |
|
Biased agonism: a real phenomenon, an over-used explanation
Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. Trying to work out what would count as evidence on biased…
|
+130 | 135 | 23k | 16mo |
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version
Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. A narrow question about…
|
+57 | 63 | 1k | 6mo |